With AAV Technology in the Clinic, NanoCor Aims to Develop shRNA-Based Heart Failure Drug | GenomeWeb

While its primary focus remains on preparing its gene therapy for chronic heart failure for phase I testing, NanoCor Therapeutics is also aiming to advance an RNAi-based treatment for the condition.

Doing so, however, will require additional financing, and the company remains on the lookout for funding opportunities, NanoCor founder Sheila Mikhail told Gene Silencing News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.